What Is Retatrutide Made From? A Canadian Guide to Its Ingredients, Structure and Safety

Medical disclaimer: This article is for general education and is not medical advice. Retatrutide is an investigational medicine, not a do-it-yourself product. Do not buy, mix or inject products sold online as “research peptides.” Speak with a physician, nurse practitioner or pharmacist about evidence-based options appropriate for you.

Quick answer: what is retatrutide made from?

Retatrutide is made from a laboratory-designed chain of 39 amino acids—the small building blocks that make up peptides and proteins—plus a fatty-acid-based side chain attached through a chemical linker. In other words, it is a synthetic, lipid-modified peptide. It is not made from animal organs, animal venom, insulin, stem cells or the three natural hormones themselves.

The amino-acid sequence is engineered to imitate selected signals associated with three hormones: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon. One retatrutide molecule can activate receptors for all three signals, which is why researchers call it a GLP-1/GIP/glucagon receptor “triple agonist.” The attached lipid portion helps the peptide remain in circulation longer, supporting once-weekly dosing in clinical trials.

That description applies to the active investigational molecule. A future commercial injection, if authorized, would also contain inactive formulation ingredients selected to keep it stable, sterile and at the correct pH. A final Canadian product label and official ingredient list cannot be assumed before a product is authorized and marketed.

Retatrutide at a glance

Type of molecule: synthetic, lipidated peptide
Length: 39 amino-acid residues
Research code: LY3437943
Targets: GLP-1, GIP and glucagon receptors
How it has been studied: once-weekly subcutaneous injection
Molecular formula commonly listed: C221H342N46O68
Approximate molecular mass: 4,731 g/mol
CAS Registry Number: 2381089-83-2
Status: investigational; availability, authorization and trial status can change

These identifiers describe the active molecule, not a finished vial’s complete contents. A molecular formula also does not establish a seller’s product identity, purity, sterility or safety.

What does “made from amino acids” mean?

Amino acids are organic molecules used by the body to build proteins and peptides. A peptide is a relatively short chain of amino acids joined by peptide bonds. The order of the amino acids matters: changing even one position can affect the molecule’s shape, stability and receptor activity.

Retatrutide’s sequence was intentionally designed. It resembles natural metabolic hormones in strategically chosen regions, but it is not simply GLP-1, GIP and glucagon mixed together. Nor is it three separate drugs combined in one syringe. It is one “unimolecular” peptide engineered to interact with three different receptor families.

This distinction answers a common version of the question “What is retatrutide made from?” Its functional inspiration comes from human hormone biology, while the investigational compound itself is chemically synthesized. The body does not naturally produce retatrutide.

The peptide backbone: a 39-amino-acid chain

The main part of retatrutide is its 39-residue peptide backbone. Most positions use familiar amino acids such as tyrosine, glutamine, glycine, threonine, phenylalanine, serine, aspartic acid, lysine, isoleucine, leucine, alanine, glutamic acid, proline and methionine. The sequence also includes modified or non-standard residues chosen to influence potency and resistance to enzymatic breakdown.

Scientific sources may display the sequence using one-letter abbreviations and special notation. That shorthand is useful to chemists but is easy to misread. It does not provide a recipe that can safely be reproduced outside regulated pharmaceutical manufacturing. Making an injectable peptide requires far more than arranging amino acids: identity, chemical purity, folding or conformation, residual solvents, microbial contamination, endotoxins, particles, concentration, pH and container integrity all require control and testing.

The World Health Organization’s proposed international nonproprietary name record gives a formal chemical description of retatrutide and identifies it as an agonist of glucagon, GIP and GLP-1 receptors. Structural research has also mapped how this engineered peptide interacts with those receptors.

The lipid side chain and linker

Retatrutide also contains a lipid side chain. “Lipidated” means that a fat-like chemical group is attached to the peptide. In retatrutide, structural research describes a fatty diacid moiety joined by a linker to a lysine residue in the peptide chain.

Why add a lipid? Small peptides can otherwise be cleared or broken down relatively quickly. A lipid side chain can promote reversible binding to albumin, an abundant protein in the blood. Albumin binding can act as a circulating reservoir and slow removal of the drug. Combined with sequence modifications that improve resistance to enzymes, this helps extend exposure and makes weekly administration scientifically plausible.

The lipid is therefore a functional part of the molecular design. It is not dietary fat, an oil filler or a separate active medicine. It does not mean that the injection is “made of fat.” It is a precisely attached chemical group on one specific position of the peptide.

Is retatrutide natural or synthetic?

Retatrutide is synthetic. Its biological targets are natural human receptors, and its design borrows features from hormone signalling, but the exact molecule is created through controlled chemical manufacturing.

Peptide medicines are commonly produced through a process such as solid-phase peptide synthesis. In simplified terms, protected amino acids are added one at a time to a growing chain anchored to a solid support. Chemists then remove protecting groups, detach the chain, add any required modifications, purify the product and confirm its identity. Industrial processes include many additional controls and may use optimized or hybrid methods.

“Synthetic” does not automatically mean unsafe, just as “natural” does not automatically mean safe. The clinically important questions are whether the exact product has been adequately studied, manufactured under appropriate quality standards, reviewed by regulators, prescribed for an appropriate patient and supplied through a legitimate pharmacy.

How can one molecule act on three hormone receptors?

Receptors are proteins that recognize chemical signals and trigger responses inside cells. Retatrutide’s sequence and three-dimensional shape allow it to bind to the receptors for GLP-1, GIP and glucagon with deliberately balanced activity.

GLP-1 receptor activity

GLP-1 signalling can increase glucose-dependent insulin secretion, slow gastric emptying and influence appetite and satiety. “Glucose-dependent” means the insulin effect is linked to glucose levels, although hypoglycaemia risk can change when related medicines are combined with insulin or sulfonylureas.

GIP receptor activity

GIP is another nutrient-responsive hormone involved in insulin secretion and metabolic regulation. Researchers are studying how combined GIP and GLP-1 activity changes appetite, glucose control and tolerability compared with targeting GLP-1 alone.

Glucagon receptor activity

Glucagon signalling has important roles in glucose regulation, substrate use and energy metabolism. On its own, glucagon can raise blood glucose. Retatrutide is designed so that glucagon-receptor activation operates alongside GLP-1- and GIP-receptor effects within the same molecule. The overall clinical result cannot be predicted by considering only one receptor.

“Triple agonist” therefore describes receptor pharmacology, not three ingredients. Retatrutide does not contain harvested GLP-1, GIP or glucagon hormones.

What else would be in a retatrutide injection?

Every injectable medicine has two ingredient categories: the active medicinal ingredient and excipients. The active ingredient produces the intended pharmacological effect. Excipients may help control pH, tonicity, stability, solubility or preservation.

Examples used in peptide injections generally can include buffers, salts, stabilizers and sterile water, but those examples are not a retatrutide ingredient list. The precise qualitative and quantitative formula is product-specific. It can also differ between a clinical-trial formulation and a future marketed presentation.

For Canadians, the reliable source for a finished medicine’s ingredients would be its authorized product monograph and pharmacy labelling after approval. Until such documentation exists for a marketed Canadian product, websites claiming a definitive list of “all retatrutide ingredients” may be describing a research formulation, extrapolating from another medicine or simply guessing.

What retatrutide is not made from

Online discussions can blur the line between a molecule’s inspiration, its active structure and a finished injection. Retatrutide is not:

a blend of semaglutide and tirzepatide;
a mixture of three natural hormones;
insulin;
a steroid or stimulant;
an animal-gland extract;
a herbal or “natural” weight-loss supplement;
a compounded recipe that consumers can verify by appearance; or
a product made safe by adding bacteriostatic water.

A clear solution or white powder cannot be visually authenticated as retatrutide. Labels, QR codes and seller-provided certificates can also be falsified. Only a legitimate, regulated supply chain plus appropriate analytical and sterility controls can provide meaningful assurance.

How is retatrutide different from semaglutide and tirzepatide?

All three are peptide-based medicines or drug candidates designed to act on metabolic hormone receptors, but their receptor profiles differ.

Semaglutide is a GLP-1 receptor agonist.
Tirzepatide activates GIP and GLP-1 receptors and is therefore called a dual agonist.
Retatrutide is designed to activate GIP, GLP-1 and glucagon receptors and is called a triple agonist.

The word “triple” does not prove that retatrutide is three times as strong or suitable for a particular person. It also does not make dose numbers interchangeable. Milligrams cannot be converted across these molecules with a simple ratio. They have different structures, receptor activity, clinical evidence, dosing schedules and regulatory status.

What have clinical studies found?

The best-known phase 2 obesity trial was a randomized, double-blind, placebo-controlled study. At 48 weeks, participants assigned to the 12 mg group had a mean weight reduction of 24.2%. That is a group average from a controlled trial, not a promise for an individual, and the trial was not designed to establish every long-term benefit or rare risk.

Gastrointestinal effects—such as nausea, diarrhea, vomiting and constipation—have been prominent in studies of incretin-related treatments. The phase 2 obesity trial also reported dose-dependent increases in heart rate that peaked earlier and later declined. Dose escalation was studied partly to manage tolerability.

Systematic reviews published later have generally found substantial reductions in body weight and improvements in several metabolic measures, while emphasizing that the evidence base remains smaller than for established treatments and that larger, longer trials are needed. A 2026 meta-analysis of incretin dual and triple agonists found more gastrointestinal adverse events and more withdrawals due to adverse events than placebo across the pooled drug class, while serious adverse events were not significantly different. Those pooled findings are not specific to every retatrutide dose or patient.

Clinical trials estimate benefits and risks under controlled conditions. They do not show that an unverified online product contains the same molecule or dose used in the research.

Is retatrutide approved or available in Canada?

Retatrutide has been studied in international phase 3 programs, including trials with Canadian locations. A trial listing is not the same as authorization for sale. Trial participation is also not routine prescribing: volunteers must meet protocol criteria, provide informed consent and be followed by the research team.

Regulatory status can change, so Canadians should verify current availability with a licensed health professional and an authorized pharmacy. If a website offers “retatrutide” before a legitimate marketed product is available, words such as “research use only,” “not for human consumption” or “peptide blend” are not safeguards. They indicate that the product is outside ordinary prescription-drug channels.

Do not interpret a seller’s Canadian address, Canadian-dollar pricing or domestic shipping as proof of authorization. Likewise, a laboratory purity percentage does not answer whether a vial is sterile, correctly dosed, free of endotoxin, stable after shipping or suitable for injection.

Why online “research peptide” versions are risky

An unauthorized vial can fail in several independent ways. It may contain no active peptide, the wrong peptide, too little or too much material, degradation products, residual synthesis chemicals, bacteria, endotoxins or visible and subvisible particles. A seller may test one batch and ship another. A posted certificate may be incomplete, copied or impossible to trace to the vial received.

Reconstituting powder at home introduces further risks. The amount of diluent, final concentration, measurement device, mixing method, storage time and injection technique all affect exposure and contamination. Confusing milligrams, millilitres and syringe “units” can produce a major dosing error.

There is no safe troubleshooting guide for an unknown injectable. Anyone who has used an unverified product and develops severe or persistent abdominal pain, repeated vomiting, fainting, confusion, breathing difficulty, facial or throat swelling, signs of dehydration or a rapidly worsening injection-site reaction should seek urgent medical care. Tell the clinician exactly what was taken and bring the packaging if it is safe to do so.

Questions to ask a Canadian clinician or pharmacist

If you are interested in retatrutide because of weight, diabetes or cardiometabolic health concerns, useful questions include:

What diagnosis and treatment goals should we address first?
Which currently authorized options have evidence for someone with my medical history?
Could any of my medicines increase gastrointestinal effects or hypoglycaemia risk?
How should nutrition, resistance exercise and protein intake be adjusted to protect lean mass during weight loss?
Are there relevant contraindications, pregnancy considerations or previous pancreatitis, gallbladder, gastrointestinal, kidney or endocrine issues to discuss?
Is a registered clinical trial appropriate, and who covers study-related care?
How can I verify that a pharmacy and product are legitimate in my province or territory?

Bring a complete medication and supplement list. A clinician’s assessment matters because obesity and diabetes care are not reducible to choosing the molecule associated with the largest headline percentage.

The bottom line

So, what is retatrutide made from? The active molecule is a synthetic chain of 39 amino acids with carefully selected sequence modifications and an attached lipid side chain. Those features create one long-acting peptide designed to activate GLP-1, GIP and glucagon receptors. It is not extracted from animals and is not a cocktail of three hormones.

That molecular explanation should not be mistaken for a finished-product ingredient list or an endorsement of products sold online. A legitimate injection requires validated manufacturing, sterile formulation, quality testing, regulatory review, professional prescribing and safe dispensing. Canadians interested in metabolic treatment should rely on licensed clinicians, authorized pharmacies and registered clinical trials—not “research peptide” vendors.

Frequently asked questions

What is the main ingredient in retatrutide?

The active investigational ingredient is retatrutide itself, a synthetic, lipid-modified peptide made of 39 amino-acid residues. A finished injection would also contain inactive formulation ingredients, but the definitive list depends on the specific authorized product and label.

Is retatrutide made from human hormones?

No. It is designed using knowledge of human hormone receptors and shares relevant structural features with metabolic peptide signals, but it is synthesized in a laboratory. It does not contain hormones extracted from people.

Is retatrutide made from animal products?

The active molecule is chemically synthesized rather than extracted from an animal organ or tissue. However, people with strict vegan, allergy or religious requirements should ask the manufacturer or pharmacist about all processing aids and excipient sources if a commercial product becomes available.

Is retatrutide a peptide?

Yes. It is a 39-amino-acid peptide with an attached fatty diacid-based side chain. The lipid modification helps prolong its time in circulation.

Does retatrutide contain GLP-1, GIP and glucagon?

No. It is one engineered molecule that activates the receptors for those three signals. “Triple agonist” refers to three receptor targets, not three hormones mixed together.

Is retatrutide the same as Ozempic or Mounjaro?

No. Those brand names refer to products with different active molecules. Semaglutide targets GLP-1 receptors; tirzepatide targets GIP and GLP-1 receptors; retatrutide is designed to target GIP, GLP-1 and glucagon receptors.

What is the molecular formula of retatrutide?

Scientific databases commonly list C221H342N46O68, with an approximate molecular mass of 4,731 g/mol. Formula variations on vendor pages can reflect errors, salts or different reporting conventions and should not be treated as proof of authenticity.

Why does retatrutide have a fatty acid attached?

The lipid side chain helps the peptide associate with albumin in the bloodstream and reduces rapid clearance. This contributes to prolonged exposure and the once-weekly schedule evaluated in trials.

How is retatrutide manufactured?

Peptides of this type can be assembled through controlled peptide synthesis, followed by attachment of the lipid-linker group, purification and extensive analytical testing. Sterile drug-product manufacturing adds formulation, filtration or aseptic processing, filling, packaging and quality controls.

Can retatrutide be compounded from raw peptide powder?

Consumers should not attempt this. A powder’s identity, potency and sterility cannot be confirmed by its appearance, and home reconstitution cannot substitute for regulated manufacturing and pharmacy controls.

Is retatrutide approved in Canada?

Authorization status can change. A clinical trial in Canada does not itself mean that routine sale or prescribing is authorized. Check current status through a licensed Canadian physician, nurse practitioner or pharmacist and obtain medicines only from legitimate pharmacies.

Can I buy retatrutide online in Canada?

Websites may advertise products under that name, but availability does not establish legality, identity, sterility or safety. Avoid products labelled “research use only” or sold without ordinary prescription and pharmacy safeguards.

What are retatrutide’s possible side effects?

Trials have commonly reported gastrointestinal effects, including nausea, diarrhea, vomiting and constipation. Heart-rate increases have also been observed. The complete benefit-risk profile, rare events and long-term safety require continued study.

Does the peptide sequence tell me whether a vial is genuine?

No. A printed sequence or molecular formula is easy to copy. Confirming a vial requires traceable manufacturing and validated analytical, potency, sterility and endotoxin testing tied to that exact batch.

Is retatrutide “GLP-3”?

“GLP-3” is an informal marketing nickname sometimes used online. It is not an accurate description of the molecule: retatrutide targets GLP-1, GIP and glucagon receptors, not a receptor called GLP-3.